Renal replacement therapy in cancer patients with acute kidney injury (Review)

Lupuşoru,Mircea; Lupuşoru,Gabriela; Ailincăi,Ioana; Frățilă,Georgiana; Andronesi,Andreea; Micu,Elena; Banu,Mihaela; Costea,Radu; Ismail,Gener

doi:10.3892/etm.2021.10296

Renal replacement therapy in cancer patients with acute kidney injury (Review)

Authors:
- Mircea Lupuşoru
- Gabriela Lupuşoru
- Ioana Ailincăi
- Georgiana Frățilă
- Andreea Andronesi
- Elena Micu
- Mihaela Banu
- Radu Costea
- Gener Ismail
View Affiliations

Affiliations: Department of Physiology 1, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Nephrology, ‘Fundeni’ Clinical Institute, 022328 Bucharest, Romania, Department of Morphology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of General Surgery, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania
Published online on: June 11, 2021 https://doi.org/10.3892/etm.2021.10296
Article Number: 864
Copyright: © Lupuşoru et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer patients are at high risk for developing acute kidney injury (AKI), which is associated with increased morbidity and mortality in these patients. Despite the progress made in understanding the pathogenic mechanisms and etiology of AKI in these patients, the main prevention consists of avoiding medication and nephrotoxic agents such as non‑steroidal anti‑inflammatory drugs, contrast agents used in medical imaging and modulation of chemotherapy regimens; when prophylactic measures are overcome and renal impairment becomes unresponsive to treatment, renal replacement therapy (RRT) is required. There are several methods of RRT that can be utilized for patients with malignancies and acute renal impairment; the choice of treatment being based on the patient characteristics. The aim of this article is to review the literature data regarding the epidemiology and management of AKI in cancer patients, the extracorporeal techniques used, choice of the appropriate therapy and the optimal time of initiation, and also the dose‑prognosis relationship.

View Figures

View References

1	Finkel K, Perazella MA and Cohen E: Acute kidney injury-Incidence, Pathogenesis and Outcomes. In: Onco-Nephrology. 1st edition. Elsevier, Amsterdam, pp270-274, 2019.
2	Bratu OG, Cherciu AI, Bumbu A, Lupu S, Marcu DR, Ionita-Radu F, Manea M, Furau C, Diaconu CC and Mischianu DL: Retroperitoneal tumours-treatment and prognosis of tumour recurrence. Rev Chim. 70:190–194. 2019.
3	Marcu DR, Ionita-Radu F, Iorga LD, Manea M, Socea B, Scarneciu I, Isvoranu G, Costache R, Diaconu CC and Bratu OG: Vascular involvement in primary retroperitoneal tumors. Rev Chim. 70:445–448. 2019.
4	Draghici T, Negreanu L, Bratu OG, Stoian AP, Socea B, Neagu TP, Stanescu AM, Manuc D and Diaconu CC: Paraneoplastic syndromes in digestive tumors: A review. Rom Biotechnol Lett. 24:813–819. 2019.
5	Perazella MA: Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 4:1275–1283. 2009.PubMed/NCBI View Article : Google Scholar
6	Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 1:1–138. 2012.
7	Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP and Sørensen HT: Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study. Eur J Intern Med. 22:399–406. 2011.PubMed/NCBI View Article : Google Scholar
8	International Agency for Research on Cancer: Europe-Global cancer Observatory. Globoscan 2018. https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf. Accessed October 28, 2020.
9	Bratu OG, Diaconu CC, Mischianu DLD, Constantin T, Stanescu AM, Bungau SG, Ionita-Radu F and Marcu RD: Therapeutic options in patients with biochemical recurrence after radical prostatectomy. Exp Ther Med. 18:5021–5025. 2019.PubMed/NCBI View Article : Google Scholar
10	Bratu O, Spînu D, Oprea I, Popescu R, Marcu D, Farcaș C, Dinu M and Mischianu D: Complications of radical retropubicprostatectomy-our experience. Romanian J Military Med. 118:23–25. 2015.PubMed/NCBI View Article : Google Scholar
11	Marcu D, Spinu D, Mischianu D, Socea B, Oprea I and Bratu OG: Oncological follow-up after radical prostatectomy. Romanian J Military Med. 120:39–42. 2017.
12	Tataru AL, Furau G, Afilon J, Ionescu C, Dimitriu M, Bratu OG, Tit DM, Bungau A and Furau C: The situation of cervical cancers in the context of female genital cancer clustering and burden of disease in Arad County. Romania J Clin Med. 8(96)2019.PubMed/NCBI View Article : Google Scholar
13	Lameire N, Van Biesen W and Vanholder R: Acute renal failure. Lancet. 365:417–430. 2005.PubMed/NCBI View Article : Google Scholar
14	Finkel KW and Kala J: Renal replacement therapy in critically Ill cancer patients. In: Oncologic Critical Care. Nates J and Price K (eds). Springer, Cham, pp1-12, 2019.
15	Daugirdas JT: Physiologic principles and urea kinetic modeling. In: Handbook of Dialysis. 5th edition. Daugirdas JT, Blake PG and Ing TS (eds). Wolters Kluwer, Philadelphia, pp34-65, 2015.
16	Fathima N, Kashif T, Janapala RN, Jayaraj JS and Qaseem A: Single-best choice between intermittent vs. continuous renal replacement therapy: A review. Cureus. 11(e5558)2019.PubMed/NCBI View Article : Google Scholar
17	PIRRT may help you improve resource utilization, patient care, early patient mobilization programs. https://www.nxstage.com/hcp/therapies/pirrt/. Accessed September 14, 2020.
18	Sherman RA, Daugirdas JT and Ing TS: Complications during hemodialysis. In: Handbook of Dialysis. 5th edition. Daugirdas JT, Blake PG and Ing TS (eds). Wolters Kluwer, Philadelphia, pp215-236, 2015.
19	Trinh-Trang-Tan MM, Cartron JP and Bankir L: Molecular basis for the dialysis disequilibrium syndrome: Altered aquaporin and urea transporter expression in the brain. Nephrol Dial Transplant. 20:1984–1988. 2005.PubMed/NCBI View Article : Google Scholar
20	Mistry K: Dialysis disequilibrium syndrome prevention and management. Int J Nephrol Renovasc Dis. 12:69–77. 2019.PubMed/NCBI View Article : Google Scholar
21	Finkel KW and Waguespack DR: Renal replacemet therapies. In: Onco-Nephrology. 1st edition. Finkel K, Perazella MA and Cohen E (eds). Elsevier, Amsterdam, pp290-298, 2019.
22	Fliser T and Kielstein JT: Technology insight: Treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol. 2:32–39. 2006.PubMed/NCBI View Article : Google Scholar
23	Berbece AN and Richardson RMA: Sustained low-efficiency dialysis in the ICU: Cost, anticoagulation, and solute removal. Kidney Int. 70:963–968. 2006.PubMed/NCBI View Article : Google Scholar
24	Baldwin I, Naka T, Koch B, Fealy N and Bellomo R: A pilot randomized controlled comparison of continuous venovenous hemofiltration and extended daily dialysis with filtration: Effect on small solutes and acid-base balance. Intensive Care Med. 33:830–835. 2007.PubMed/NCBI View Article : Google Scholar
25	Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H and Fliser D: Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: A randomized controlled study. Am J Kidney Dis. 43:342–349. 2004.PubMed/NCBI View Article : Google Scholar
26	Schwenger V, Weigand MA, Hoffmann O, Dikow R, Kihm LP, Seckinger J, Miftari N, Schaier M, Hofer S, Haar C, et al: Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury-a randomized interventional trial: The REnal replacement therapy study in intensive care unit patiEnts. Crit Care. 16(R140)2012.PubMed/NCBI View Article : Google Scholar
27	Cullis B, Abdelraheem M, Abrahams G, Balbi A, Cruz DN, Frishberg Y, Koch V, McCulloch M, Numanoglu A, Nourse P, et al: Peritoneal dialysis for acute kidney injury. Perit Dial Int. 34:494–517. 2014.PubMed/NCBI View Article : Google Scholar
28	Schiffl H, Lang SM and Fischer R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 346:305–310. 2002.PubMed/NCBI View Article : Google Scholar
29	Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P and La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet. 356:26–30. 2000.PubMed/NCBI View Article : Google Scholar
30	Uchino S: The epidemiology of acute renal failure in the world. Curr Opin Crit Care. 12:538–543. 2006.PubMed/NCBI View Article : Google Scholar
31	Kellum JA, Angus DC, Johnson JP, Leblanc M, Griffin M, Ramakrishnan N and Linde-Zwirble WT: Continuous versus intermittent renal replacement therapy: A meta-analysis. Intensive Care Med. 28:29–37. 2002.PubMed/NCBI View Article : Google Scholar
32	Tonelli M, Manns B and Feller-Kopman D: Acute renal failure in the intensive care unit: A systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis. 40:875–885. 2002.PubMed/NCBI View Article : Google Scholar
33	Sandy D, Moreno L, Lee J and Paganini EP: A randomized stratified, dose equivalent comparison of continuous veno-venous hemodialysis (CVVHD) vs intermittent hemodialysis (IHD) support in ICU acute renal failure patients (ARF). J Am Soc Nephrol. 9(225A)1998.
34	John S, Griesbach D, Baumgartel M, Weihprecht H, Schmieder RE and Geiger H: Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: A prospective, randomized clinical trial. Nephrol Dial Transplant. 16:320–327. 2001.PubMed/NCBI View Article : Google Scholar
35	Mehta RL, McDonald BR, Gabbai FB, Pahl M, Pascual MT, Farkas A and Kaplan RM: Collaborative Group for Treatment of ARF in the ICU. A randomized clinical trial of continuous vs intermittent dialysis for acute renal failure. Kidney Int. 60:1154–1163. 2001.PubMed/NCBI View Article : Google Scholar
36	Uehlinger DE, Jakob SM, Eichelberger M, et al: A randomized, controlled single center study for the comparison of continuous renal replacement therapy with intermittent hemodialysis in critically ill patients with acute renal failure. J Am Soc Nephrol. 12(278A)2001.
37	Leaf DE and Waika SS: IDEAL-ICU in context. Clin J Am Soc Nephrol. 14:1264–1267. 2019.PubMed/NCBI View Article : Google Scholar
38	Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, Boanta A, Gerß J and Meersch M: Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN randomized clinical trial. JAMA. 315:2190–2199. 2016.PubMed/NCBI View Article : Google Scholar
39	Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, Boyer A, Chevrel G, Lerolle N, Carpentier D, et al: for the AKIKI study group: initiation strategies for renal-replacement therapy in the intensive care unit. N Eng J Med. 375:122–133. 2016.PubMed/NCBI View Article : Google Scholar
40	Teo BW, Messer JS, Chua HR, How P and Demirjian S: Continuous Renal Replacement Therapies. In: Handbook of Dialysis. 5th edition. Daugirdas JT, Blake PG and Ing TS (eds). Wolters Kluwer, Philadelphia, pp268-304, 2015.
41	Rastegar M, Kitchlu A and Shirali AC: Tumor lysis syndrome. In: Onco-Nephrology. 1st edition. Daugirdas JT, Blake PG and Ing TS (eds). Elsevier, Amsterdam, pp275-280, 2019.
42	Kiprov DD, Sanchez A and Pusey C: Therapeutic apheresis. In: Handbook of Dialysis. 5th edition. Daugirdas JT, Blake PG and Ing TS (eds). Wolters Kluwer, Philadelphia, pp333-359, 2015.
43	Favà A, Fulladosa X, Montero N, Draibe J, Torras J, Gomà M and Cruzado JM: Treatment of multiple myeloma with renal involvment: the nephrologist's view. CKD. 11:777–785. 2018.PubMed/NCBI View Article : Google Scholar
44	Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, et al: Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 22:1129–1136. 2011.PubMed/NCBI View Article : Google Scholar
45	Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX and Churchill DN: Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med. 143:777–784. 2005.PubMed/NCBI View Article : Google Scholar
46	Gondouin B and Hutchison CA: High cut-off dialysis membranes: Current uses and future potential. Adv Chronic Kidney Dis. 18:180–187. 2011.PubMed/NCBI View Article : Google Scholar
47	Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P and Grima D: Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 27:3823–3828. 2012.PubMed/NCBI View Article : Google Scholar
48	Finkel K and Fabbrini P: Paolo fabbrini. High cut-off hemodialysis for myeloma cast nephropathy-do we finally have an answer? J Onco-Nephrol. 1:67–70. 2017.
49	Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A and Cockwell P: European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials. 9(55)2008.PubMed/NCBI View Article : Google Scholar
50	Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, Joly B, Peraldi MN, Arnulf B, Vigneau C, et al: Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: A randomized clinical trial. JAMA. 318:2099–2110. 2017.PubMed/NCBI View Article : Google Scholar
51	Vallée AG, Chenine L, Leray-Moragues H, Patrier L, Cognot C, Cartron G, Cristol JP and Canaud B: Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: Preliminary quantitative study. Nephrol Dial Transplant. 26:3627–3633. 2011.PubMed/NCBI View Article : Google Scholar
52	Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR and Krieter DH: . Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 1:165–172. 2016.PubMed/NCBI View Article : Google Scholar
53	Zweigart C, Boschetti-de-Fierro A, Hulko M, Nilsson LG, Beck W, Storr M and Krause B: Medium cut-off membranes-closer to the natural kidney removal function. Int J Artif Organs. 40:328–334. 2017.PubMed/NCBI View Article : Google Scholar
54	Krishnasamy R, Hawley CM, Jardine MJ, Roberts MA, Cho YJ, Wong MG, Heath A, Nelson CL, Sen A, Mount PF, et al: Design and methods of the REMOVAL-HD study: A tRial evaluating Mid cut-Off value membrane clearance of albumin and light chains in haemoDialysis patients. BMC Nephrol. 19(89)2018.PubMed/NCBI View Article : Google Scholar
55	Ronco C, Marchionna N, Brendolan A, Neri M, Lorenzin A and Rueda AJ: Expanded haemodialysis: Expanded haemodialysis: From operational mechanism to clinical results. Nephrol Dial Transplant. 33 (Suppl 3):iii41–iii47. 2018.PubMed/NCBI View Article : Google Scholar
56	Pérez-García R and Alcázar R: The dialyser in the year 2017: Much more than a membrane. Nefrologia. 38:4–7. 2018.PubMed/NCBI View Article : Google Scholar : (In English, Spanish).